This article has been updated to correct details regarding the Florida state license.
NEW YORK (GenomeWeb) – Colorectal cancer testing firm Clinical Genomics today said that it has received licensure from Florida authorities to offer its Colvera colorectal cancer test to residents of the state.
The license from the Florida Agency for Healthcare Administration allows the Bridgewater, New Jersey-based firm to offer the liquid biopsy test for identifying ctDNA for detecting residual disease and early detection of recurrence in post-treatment patients.
Florida is one of a handful of states that requires state licensures — in addition to CLIA certification of labs — for firms to provide certain tests to state residents. As a result of the licensure, Clinical Genomics will be able to make Colvera available to about 10,000 patients in Florida who are treated for colorectal cancer each year, Clinical Genomics Pathology Vice President of Operations and laboratory site director John Alsobrook said in a statement.